Proteome Sciences declared on Monday that it has secured a third contract from a US biopharmaceutical client to develop a new mass-spectrometry-based assay at its Frankfurt facility ahead of the customer's planned clinical trial programme in 2026.
The GCLP-compliant initial phase will support assay development for use in a trial scheduled to begin at the end of Q1 2026. Follow-on phases are expected to mirror the scope of contracts awarded in February 2025. A portion of the work will be recognised in the current financial year, with the remainder completing by the end of Q1 2026.
Proteome Sciences provides contract proteomics services for drug discovery, development and biomarker identification, including SysQuant, TMTMS2, Super-Depletion and TMTcalibrator, alongside targeted mass-spectrometry assay development.
Relay Therapeutics wins FDA breakthrough status for zovegalisib in breast cancer treatment
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Valneva and Instituto Butantan launch pilot chikungunya vaccination campaign in Brazil
Lupin launches Dasatinib tablets in US market
WuXi Biologics enters into licence and research service agreement with Vertex Pharmaceuticals
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Astrazeneca Imfinzi perioperative regimen gains positive EU CHMP opinion in early gastric cancer
I Peace generates human iPS cells from NKT cells and offers them for research use
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
AstraZeneca agrees obesity and type 2 diabetes collaboration with CSPC
Ascletis Pharma Inc reports topline results from Phase III open-label study of denifanstat
Innovative Molecules GmbH completes Phase 1 clinical development programme for adibelivir
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA